» Articles » PMID: 15246916

Comparison of Circulating Levels of Interleukin-6 and Tumor Necrosis Factor-alpha in Hypertrophic Cardiomyopathy and in Idiopathic Dilated Cardiomyopathy

Overview
Journal Am J Cardiol
Date 2004 Jul 13
PMID 15246916
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

It is known from the literature that the circulating levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are elevated in heart failure and idiopathic dilated cardiomyopathy (IDC). Few convincing data are available on the production of cytokines in hypertrophic cardiomyopathy (HC). The levels of circulating IL-6, the soluble form of the IL-6 receptor (sIL-6R), and TNF-alpha in 19 patients with HC, 31 patients with IDC, and 20 healthy subjects (control group) were examined and compared with their clinical parameters. The levels of TNF-alpha and circulating IL-6 proved to be elevated in the sera of patients with IDC. In contrast, the level of TNF-alpha was not elevated in HC, although the levels of IL-6 and sIL-6R were significantly higher than those in the sera of patients with IDC. Although elevated levels of IL-6 may correlate with the extent of left ventricular dysfunction in IDC, the markedly elevated IL-6 levels did not correlate with left ventricular function in HC. The markedly elevated TNF-alpha levels in IDC were associated with the elevated IL-6 levels, probably because of an inflammatory process and/or heart failure. In contrast, in HC, in which the New York Heart Association functional class was actually good, the even higher IL-6 and sIL-6R levels were not associated with a TNF-alpha elevation. In HC, the IL-6 and sIL-6R elevations were due to another mechanism, probably by way of the cardiotrophin-associated gp130 receptor. The sources of IL-6 production in HC are not clear yet.

Citing Articles

Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.

Fragkiadakis K, Ktena N, Kalantidou A, Dermitzaki E, Anastasiou I, Papathanassiou S Cells. 2024; 13(16.

PMID: 39195218 PMC: 11352956. DOI: 10.3390/cells13161328.


A personalized mRNA signature for predicting hypertrophic cardiomyopathy applying machine learning methods.

Gu J, Zhao Y, Ben Y, Zhang S, Hua L, He S Sci Rep. 2024; 14(1):17023.

PMID: 39043774 PMC: 11266364. DOI: 10.1038/s41598-024-67201-8.


Prognostic value of albumin to fibrinogen ratio for mortality in patients with hypertrophic cardiomyopathy.

Li L, Ban C, Ruan H, Zhang M, Wang Z, Ma M BMC Cardiovasc Disord. 2023; 23(1):559.

PMID: 37974066 PMC: 10652625. DOI: 10.1186/s12872-023-03562-8.


The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.

Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J Cells. 2023; 12(13).

PMID: 37443814 PMC: 10341218. DOI: 10.3390/cells12131780.


Cytokine Pathways in Cardiac Dysfunction following Burn Injury and Changes in Genome Expression.

Dejesus J, Wen J, Radhakrishnan R J Pers Med. 2022; 12(11).

PMID: 36579591 PMC: 9696755. DOI: 10.3390/jpm12111876.